Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines

Oncology Reports

Volumn 29, Issue 5, 2013, Pages 2039-2045

  Fialova, Barbora ^a   Trtkova, Katerina Smesny ^a   Paskova, Lenka ^a   Langova, Katerina ^a   Kolar, Zdenek ^a  

^a PALACKÝ UNIVERSITY   (Czech Republic)

Author keywords

Androgen receptor; DNA methylation; Epigenetics; Histone acetylation; Prostate cancer

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANDROGEN; ANDROGEN RECEPTOR; BUTYRIC ACID; GENOMIC DNA;

5' UNTRANSLATED REGION; ANDROGEN DEPRIVATION THERAPY; AR GENE; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CASTRATION RESISTANT PROSTATE CANCER; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; CPG ISLAND; DEACETYLATION; DNA METHYLATION; DRUG CYTOTOXICITY; GENE ACTIVATION; GENE EXPRESSION REGULATION; GENE INACTIVATION; GENE SEQUENCE; GENETIC ANALYSIS; HISTONE ACETYLATION; HUMAN; HUMAN CELL; IMMUNOPRECIPITATION; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

5' UNTRANSLATED REGIONS; ACETYLATION; ANDROGENS; AZACITIDINE; BUTYRIC ACID; CELL LINE, TUMOR; CELL SURVIVAL; DNA; DNA METHYLATION; HISTONE DEACETYLASE INHIBITORS; HISTONE DEACETYLASES; HISTONES; HUMANS; MALE; METHYLTRANSFERASES; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; RECEPTORS, ANDROGEN;

EID: 84876247103     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2344     Document Type: Article

References (36)

1. Knudsen K and Kelly WK: Outsmarting androgen receptor: creative approaches for targeting aberrant androgen signaling in advanced prostate cancer. Expert Rev Endocrinol Metab 6: 483-493, 2011.
2. Gao F, Yang M, Luo L and Wu XH: Local insulin-like growth factor-I of ventral prostate was upregulated during long-term castration and may function through the autocrine system. Prostate Cancer Prostatic Dis 14: 136-142, 2011.
3. Culig Z and Puhr M: Interleukin-6: a multifunctional targetable cytokine in human prostate cancer. Mol Cell Endocrinol 360: 52-58, 2012.
4. Mohler JL, Gregory CW, Ford OH III, Kim D, Weaver CM, Petrusz P, Wilson EM and French FS: The androgen axis in recurrent prostate cancer. Clin Cancer Res 10: 440-448, 2004. (Pubitemid 38173980)
5. Mohler JL: Castration-recurrent prostate cancer is not androgen-independent. Adv Exp Med Biol 617: 223-234, 2008.
6. Scher HI and Sawyers CL: Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol 23: 8253-8261, 2005. (Pubitemid 46211563)
7. Imamura T: Epigenetic setting for long-term expression of estrogen receptor α and androgen receptor in cells. Horm Behav 59: 345-352, 2011.
8. Esteller M: Epigenetics in cancer. N Engl J Med 358: 1148-1159, 2008.
9. Gao L and Alumkal J: Epigenetic regulation of androgen receptor signaling in prostate cancer. Epigenetics 5: 100-104, 2010.
10. Martinez-Arguelles DB and Papadopoulos V: Epigenetic regulation of the expression of genes involved in steroid hormone biosynthesis and action. Steroids 75: 467-476, 2010.
11. Terao Y, Nishida J, Horiuchi S, Rong F, Ueoka Y, Matsuda T, Kato H, Furugen Y, Yoshida K, Kato K and Wake N: Sodium butyrate induces growth arrest and senescence-like phenotypes in gynecologic cancer cells. Int J Cancer 94: 257-267, 2001. (Pubitemid 32911422)
12. Jüttermann R, Li E and Jaenisch R: Toxicity of 5-aza-2′- deoxycytidine to mammalian cells is mediated primarily by covalent trapping of DNA methyltransferase rather than DNA demethylation. Proc Natl Acad Sci USA 91: 11797-11801, 1994.
13. Zorn CS, Wojno KJ, McCabe MT, Kuefer R, Gschwend JE and Day ML: 5-Aza-2′-deoxycytidine delays androgen-independent disease and improves survival in the transgenic adenocarcinoma of the mouse prostate mouse model of prostate cancer. Clin Cancer Res 13: 2136-2143, 2007. (Pubitemid 46649883)
14. McCabe MT, Low JA, Daignault S, Imperiale MJ, Wojno KJ and Day ML: Inhibition of DNA methyltransferase activity prevents tumorigenesis in a mouse model of prostate cancer. Cancer Res 66: 385-392, 2006. (Pubitemid 43166046)
15. Gravina GL, Marampon F, Di Staso M, Bonfili P, Vitturini A, Jannini EA, Pestell RG, Tombolini V and Festuccia C: 5-Azacitidine restores and amplifies the bicalutamide response on preclinical models of androgen receptor expressing or deficient prostate tumors. Prostate 70: 1166-1178, 2010.
16. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S and Chung LW: Derivation of androgen independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 57: 406-412, 1994. (Pubitemid 24168617)
17. Carmichael J, DeGraff WG, Gazdar AF, Minna JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity testing. Cancer Res 47: 936-942, 1987. (Pubitemid 17027905)
18. Malikova J, Swaczynova J, Kolar Z and Strnad Z: Anticancer and antiproliferative activity of natural brassinosteroids. Phytochemistry 69: 418-426, 2008.
19. Tilley WD, Marcelli M and McPhaul MJ: Expression of the human androgen receptor gene utilizes a common promoter in diverse human tissues and cell lines. J Biol Chem 265: 13776-13781, 1990.
20. Trtkova K, Paskova L, Matijescukova N, Strnad M and Kolar Z: Binding of AR to SMRT/N-CoR complex and its co-operation with PSA promoter in prostate cancer cells treated with natural histone deacetylase inhibitor NaB. Neoplasma 57: 406-414, 2010.
21. Jarrard DF, Kinoshita H, Shi Y, Sandefur C, Hoff D, Meisner LF, Chang C, Herman JG, Isaacs WB and Nassif N: Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells. Cancer Res 58: 5310-5314, 1998. (Pubitemid 28551106)
22. Nakayama T, Watanabe M, Suzuki H, Toyota M, Sekita N, Hirokawa Y, Mizokami A, Ito H, Yatani R and Shiraishi T: Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest 80: 1789-1796, 2000. (Pubitemid 32012748)
23. Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, Choon A, Reznikoff CR, Bova GS, Friedl A and Jarrard DF: Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res 60: 3623-3630, 2000. (Pubitemid 30482185)
24. Mancini DN, Singh SM, Archer TK and Rodenhiser DI: Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB and SP1 transcription factors. Oncogene 18: 4108-4119, 1999. (Pubitemid 29363918)
25. Mishra DK, Chen Z, Wu Y, Sarkissyan M, Koeffler HP and Vadgama JV: Global methylation pattern of genes in androgen-sensitive and androgen-independent prostate cancer cells. Mol Cancer Ther 9: 33-45, 2010.
26. Cameron EE, Bachman KE, Myöhänen S, Herman JG and Baylin SB: Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 21: 103-107, 1999. (Pubitemid 29036293)
27. Dobosy JR and Selker EU: Emerging connections between DNA methylation and histone acetylation. Cell Mol Life Sci 58: 721-727, 2001. (Pubitemid 32553029)
28. Ahmed H: Promoter methylation in prostate cancer and its application for the early detection of prostate cancer using serum and urine samples. Biomark Cancer 2: 17-33, 2010.
29. Emanuele S, Lauricella M and Tesoriere G: Histone deacetylase inhibitors: apoptotic effects and clinical implications (Review). Int J Oncol 33: 637-646, 2008.
30. Marks PA and Xu WS: Histone deacetylase inhibitors: potential in cancer therapy. J Cell Biochem 107: 600-608, 2009.
31. Zhu WG and Otterson GA: The interaction of histone deacetylase inhibitors and DNA methyltransferase inhibitors in the treatment of human cancer cells (Review). Curr Med Chem Anticancer Agents 3: 187-199, 2003.
32. VanOosten RL, Earel JK Jr and Griffith TS: Histone deacetylase inhibitors enhance Ad5-TRAIL killing of TRAIL-resistant prostate tumor cells through increased caspase-2 activity. Apoptosis 12: 561-571, 2007.
33. Qiu J, Gao Z and Shima H: Growth of human prostate cancer cells is significantly suppressed in vitro with sodium butyrate through apoptosis. Oncol Rep 27: 160-167, 2012.
34. Walton TJ, Li G, Seth R, McArdle SE, Bishop MC and Rees RC: DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate 68: 210-222, 2008. (Pubitemid 351186233)
35. Tilley WD, Bentel JM, Aspinall JO, Hall RE and Horsfall DJ: Evidence for a novel mechanism of androgen resistance in the human prostate cancer cell line, PC-3. Steroids 60: 180-186, 1995.
36. Mizokami A and Chang C: Induction of translation by the 5′-untranslated region of human androgen receptor mRNA. J Biol Chem 269: 25655-25659, 1994. (Pubitemid 24336260)